Detalles de la búsqueda
1.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Ann Oncol
; 34(6): 531-542, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062416
2.
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ann Oncol
; 29(8): 1777-1783, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29893791
3.
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Ann Oncol
; 28(11): 2768-2772, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945833
4.
Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772].
Ann Oncol
; 33(3): 355, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35012798
5.
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast Cancer Res Treat
; 166(3): 775-785, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28822007
6.
Pathogenesis of genital herpes simplex virus infection in mice. III. Comparison of the virulence of wild and mutant strains.
Med Microbiol Immunol
; 173(4): 187-96, 1984.
Artículo
en Inglés
| MEDLINE | ID: mdl-6096684
Resultados
1 -
6
de 6
1
Próxima >
>>